Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Currently, 13 CAR-T treatments have received regulatory approval. Blood cancers have dominated the development pipeline of ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...

Malabar Cancer Centre (MCC) in Kannur successfully implements CAR T-cell therapy, a groundbreaking treatment for blood cancer ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.